Xenon Pharmaceuticals Inc. (XENE)
NEUTRALFondamental
29
Prix
$60.63
Capitalisation boursière
$5.88B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$8M
Exercice clos le 31/12/2025
Résultat net
$-346M
Exercice clos le 31/12/2025
Flux de trésorerie libre
$-280M
Capitaux propres totaux
$582M
Passif total
$51M
Ratio de liquidité général
21.02
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$81.30
Prix actuel
$60.63
Marge de sécurité
+25.4%
Fourchette de juste valeur
$77.23 - $85.36
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-59.5%
Ratio P/B
4.72
P/FCF
-
Marge brute
-
ROIC
-27.9%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-27.9%
WACC
8.0%
ROIC − WACC
-35.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (6)
- Price CAGR 22.95%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 96% Buy
- Share Dilution 1.9%
Échoué (11)
- EPS shows upward trend
- ROIC -27.9%
- P/B Ratio 4.72
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -44.0%
- Revenue Growth 5Y -25.3%
- Earnings Surprise avg 0.5%
- Piotroski F-Score 2/9
Indisponible (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Le nombre d'actions est stable
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director | 49 |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer | 54 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 57 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 54 |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer | 61 |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer | 53 |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources | 65 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 64 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 64 |
| Ms. Colleen Alabiso | Senior Vice President of Corporate Affairs | - |
Risque d'audit
5
Risque du conseil
1
Risque de rémunération
8
Risque droits des actionnaires
3
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for XENE, sourced from Markets Gazette.
- 3/9/2026POSITIVEXenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals Inc. experienced a significant share price surge following the release of positive Phase 3 clinical trial data for its drug azetukalner. The pivotal study demonstrated a substantial reduction in monthly seizures for patients treated with the drug. This success paves the way for Xenon to file for FDA approval in 2026. The strong clinical results and clear regulatory path are highly encouraging for investors, potentially positioning azetukalner as a significant new treatment option and driving future revenue growth for the company.
via Markets Gazette